Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLK), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
Outlook Therapeutics, Inc. (OTLK) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative monoclonal antibody (mAb) therapies for ocular diseases. The cornerstone of their pipeline is ONS-5010, also known as Lytenava™, which targets various ophthalmic indications, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
Outlook Therapeutics aims to address the unmet needs in ophthalmology with cost-effective and accessible treatment options. The company leverages its proprietary BioSymphony™ platform to expedite the development of these complex biologics, ensuring high standards of quality and compliance with regulatory requirements.
Recent achievements include the successful completion of Phase 3 clinical trials for ONS-5010. These promising results bring Outlook Therapeutics a step closer to FDA approval and commercialization. The company is also exploring strategic partnerships to enhance its market reach and streamline its operations.
Financially, Outlook Therapeutics shows a robust commitment to R&D, as evidenced by their investment in clinical trials and manufacturing capabilities. Their integrated approach, combining in-house development and scalable production, positions them as a competitive player in the biosimilar market.
For investors, Outlook Therapeutics represents a unique opportunity in the biopharmaceutical sector focused on ophthalmology. The company’s strategic direction and ongoing projects highlight its potential for significant growth and market impact.
Outlook Therapeutics has re-submitted its Biologics License Application (BLA) for ONS-5010 to the FDA, aiming to become the first approved ophthalmic formulation of bevacizumab for wet AMD. This follows improvements based on FDA feedback. The company is confident in its submission, citing compelling clinical trial data from the NORSE studies. ONS-5010 demonstrates significant efficacy with 41.7% of patients gaining at least 15 letters of vision. The company is also preparing for a potential 2023 launch by establishing partnerships and building distribution capabilities.
Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced the appointment of Dr. Julia A. Haller to its Board of Directors on August 15, 2022. Dr. Haller, an esteemed ophthalmologist and leader in retinal research, brings extensive experience and expertise, enhancing the company's strategic direction as it advances ONS-5010, an investigational ophthalmic formulation of bevacizumab. This formulation aims to provide FDA-approved treatment options for retinal diseases, addressing the need for safe and effective therapies, particularly for conditions like wet AMD.
Outlook Therapeutics, Inc. (Nasdaq: OTLK) reported a Q3 net loss of $17.5 million, or $0.08 per share, up from a $12.2 million loss last year. The company plans to re-submit its Biologics License Application (BLA) for ONS-5010 by September 2022, following positive FDA feedback. ONS-5010, if approved, would be the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications, addressing the public health risk of off-label usage. The company has $26 million in cash, estimated to fund operations into Q1 2023, and is collaborating with partners for commercial launch preparations.
Outlook Therapeutics (Nasdaq: OTLK) announced that President and CEO Russ Trenary will present at the H.C. Wainwright 2nd Annual Ophthalmology Conference on August 17. This event focuses on the development of ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab for retinal conditions. Attendees can engage in virtual one-on-one meetings with the management team. A video webcast of the presentation will be available on-demand starting August 17 at 7:00 AM ET on the company's website, archived for 90 days.
Outlook Therapeutics (OTLK) has announced the full cash pre-payment of its unsecured convertible promissory note, dated November 4, 2020, to strengthen its financial position ahead of a potential FDA approval for ONS-5010 (bevacizumab-vikg). The repayment, which eliminates the risk of dilution from converting the note into common stock at a discount, allows the company to maintain investor confidence. The note, which had a face amount of $10,220,000, was initially amended to extend its maturity and increase interest rates, reflecting the company’s focus on upcoming regulatory hurdles.
Outlook Therapeutics (OTLK) has confirmed its plan to re-submit the Biologics License Application (BLA) for its investigational drug ONS-5010 (bevacizumab-vikg) to the FDA by September 2022. This follows a voluntary withdrawal of the original submission in May 2022 to address FDA requests for additional information. The company aims to provide the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications such as wet age-related macular degeneration.
Outlook Therapeutics (OTLK) announced that the FDA has requested more information to complete its Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) for treating wet age-related macular degeneration. The company voluntarily withdrew the BLA and aims to resubmit a revised application by September 2022. CEO Russell Trenary expressed confidence in the product's potential to be the first FDA-approved ophthalmic formulation of bevacizumab. ONS-5010 is designed to offer a safer alternative to unapproved repackaged formulations used in current treatments for retinal diseases.
Outlook Therapeutics, a pre-commercial biopharmaceutical company, will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, FL. The company is focused on developing ONS-5010/LYTENAVA™, an investigational therapy aimed at being the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications. The presentation will be led by Lawrence Kenyon, Chief Financial Officer, with opportunities for one-on-one meetings with investors. A video webcast of the presentation will be available on May 24, 2022.
Outlook Therapeutics (Nasdaq: OTLK) has submitted a Biologics License Application (BLA) for ONS-5010, branded as LYTENAVA™, for treating wet age-related macular degeneration (AMD). The company anticipates a PDUFA date announcement in June 2022 and is ramping up pre-launch plans, supported by sufficient funding. Financial results for Q2 2022 show a net loss of $19.7 million, compared to $13.1 million in the previous year, with cash reserves at $58.4 million. Outlook is optimistic about commercial partnerships and aims for global market registration.
Outlook Therapeutics (Nasdaq: OTLK) announced that COO Terry Dagnon will participate in the Retina World Congress 2022 from May 12-15 in Fort Lauderdale, Florida. Dagnon will discuss ONS-5010 (LYTENAVA™), an investigational formulation of bevacizumab for retinal diseases, including wet AMD. The FDA has received a Biologics License Application (BLA) for ONS-5010, which, if approved, would provide 12 years of marketing exclusivity. This product aims to address safety concerns related to off-label IV use of bevacizumab currently prevalent in the retina community.
FAQ
What is the current stock price of Outlook Therapeutics (OTLK)?
What is the market cap of Outlook Therapeutics (OTLK)?
What does Outlook Therapeutics, Inc. specialize in?
What is ONS-5010?
What are the key therapeutic areas for Outlook Therapeutics?
Has ONS-5010 completed clinical trials?
What is the BioSymphony™ platform?
Is Outlook Therapeutics involved in any partnerships?
What opportunities does Outlook Therapeutics offer to investors?
What is the financial condition of Outlook Therapeutics?
What recent achievements has Outlook Therapeutics made?
How does Outlook Therapeutics ensure the quality of its products?
